†Median OS not reached at 21 months for eight patients with primary PCL. CE: Cyclophosphamide, etoposide; dex: Dexamethasone; M-80: Intermediate-dose melphalan, dexamethasone; MP: Melphalan ...
Yale scientists have discovered a promising way to trigger immune responses against certain tumors, using a lupus-related antibody that can slip, undetected, into "cold" tumors and flip on an ...
Rutgers Health researchers have discovered that networks of misplaced immune cells drive an aggressive lung disease, ...
News-Medical.Net on MSN2d
Yale study unlocks potential of lupus-related antibody to target cold tumorsYale scientists have discovered a promising way to trigger immune responses against certain tumors, using a lupus-related antibody that can slip, undetected, into "cold" tumors and flip on an immune ...
The Lupus Research Alliance (LRA) is proud to announce the inaugural recipients of the new Targeted Research Program on ...
The FDA has agreed to review an application from Roche that seeks approval in the U.S. of obinutuzumab as a treatment for ...
Scientists have discovered a promising way to trigger immune responses against certain tumors, using a lupus-related antibody that can slip, undetected, into 'cold' tumors and flip on an immune ...
NEW YORK, March 20, 2025 /PRNewswire/ -- The Lupus Research Alliance (LRA) is proud to announce the inaugural recipients of the new Targeted Research Program on Engineered Cell Therapies for Lupus ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback